Antimicrobial ReportsBreakthrough Candidemia In Children On MicafunginFunaki, Takanori MD*; Miyairi, Isao MD, PhD*,†Author Information From the *Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan †Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee. Accepted for publication January 24, 2018. This work was supported by a grant from the National Center for Child Health and Development 27-6 to I.M. and 24–31 to T.F. I.M. has received honorarium for lectures sponsored by Astellas Pharma Inc. The other author has no conflicts of interest to disclose. Address for correspondence: Takanori Funaki, MD, Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, 157-8535 Tokyo, Japan. E-mail: firstname.lastname@example.org. The Pediatric Infectious Disease Journal: December 2018 - Volume 37 - Issue 12 - p 1258-1260 doi: 10.1097/INF.0000000000002020 Buy Metrics Abstract We identified 8 pediatric patients on micafungin (MCFG; ≥3 doses) at our institution who had breakthrough candidemia (BC). The causative strains of the BC were Candida parapsilosis in 7 patients. The minimum inhibitory concentration of MCFG was ≤1 µg/mL (susceptible) in all 8 isolates. Immunocompromised patients may develop BC caused by MCFG-susceptible strains. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.